Business Context and Reporting Period
This Form 6-K filing by ImmunoPrecise Antibodies Ltd. (Mindwalk Holdings Corp.) covers the month of October 2021. The registrant is a foreign issuer reporting pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The filing is primarily an informational report regarding a change in the company's independent auditors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notice of corporate governance changes rather than a financial performance report.
Material Changes
The material change disclosed in this filing is the replacement of the company's independent auditor:
- Former Auditor: Crowe MacKay LLP (resigned/terminated).
- Successor Auditor: Grant Thornton LLP (appointed).
- Effective Date: The Notice of Change of Auditor was dated October 13, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard disclosure of the auditor transition. The filing includes letters from both the former and successor auditors confirming the change.
Key Facts for Investor Verification
- Verify the reasons for the auditor change by reviewing the accompanying letters from Crowe MacKay LLP and Grant Thornton LLP.
- Confirm that the change in auditors does not indicate any disagreement with the former auditor regarding accounting principles or financial statement disclosures.
- Note that this filing does not contain updated financial results; investors should refer to the most recent Form 20-F or 40-F for financial data.